Detected ·
Oyster Therapeutics
$60MSeries A
Oyster Therapeutics (formerly Kesmalea Therapeutics) announced a $60M Series A-2 financing alongside a new research collaboration with Massachusetts General Hospital, advancing its oral, brain-penetrant tau degrader and SELFTAC targeted protein degradation platform.
- Website
- oyster-tx.com
- linkedin.com/company/98348645
- Amount
- $60 000 000 USD
- Stage
- Series A
- Event
- Funding round
- Detected
- 2026-11-10 16:04:03 UTC
- Signal ID
- fa508c26-c162-4ea8-a586-e0fc0c85f973
As the API returns it
{
"id": "fa508c26-c162-4ea8-a586-e0fc0c85f973",
"created_at": "2026-11-10T16:04:03.670079Z",
"company_name": "Oyster Therapeutics",
"company_website_url": "oyster-tx.com",
"company_linkedin_url": "https://www.linkedin.com/company/98348645",
"event_type": "funding",
"funding_amount": 60000000,
"funding_currency": "USD",
"funding_stage": "series_a",
"message": "*Oyster Therapeutics (formerly Kesmalea Therapeutics) announced a $60M Series A-2 financing alongside a new research collaboration with Massachusetts General Hospital, advancing its oral, brain-penetrant tau degrader and SELFTAC targeted protein degradation platform.*"
}